Aston University and Comvita File Patent for Enhanced Mānuka Honey Formulation Against Drug-Resistant Bacteria
核心洞察
Aston University and New Zealand company Comvita (搜索) have filed a patent for a breakthrough Mānuka honey (搜索) formulation that demonstrates superior antimicrobial activity compared to Mānuka honey alone.
Early results show the formulation is effective against highly drug-resistant bacterial species including MRSA (搜索) and other pathogens causing serious hospital infections worldwide.
The development addresses the urgent global challenge of antimicrobial resistance (搜索), which the WHO projects could cause up to 10 million deaths annually by 2050.
Aston University's Dr Jonathan Cox and New Zealand Mānuka honey (搜索) company Comvita (搜索) have filed a patent for a novel formulation that harnesses the antimicrobial properties of Mānuka honey to combat drug-resistant bacterial infections. The breakthrough represents a significant milestone in their three-year research collaboration and offers a promising approach to address the growing global challenge of antimicrobial resistance (搜索) (AMR).
Enhanced Antimicrobial Activity
The patented formulation demonstrates superior effectiveness against bacteria compared to Mānuka honey (搜索) alone. Early results show the enhanced formulation is effective against many highly drug-resistant bacterial species, including methicillin-resistant Staphylococcus aureus (MRSA (搜索)) and other pathogens that are major causes of serious hospital infections and deaths worldwide.
Dr Cox, senior lecturer in microbiology in Aston University School of Biosciences, emphasized the urgent need for new therapeutic options. "Antibiotic-resistant infections such as Mycobacterium abscessus (搜索) are incredibly difficult to treat, and new therapeutic options are urgently needed," he said. "Our work shows that Mānuka honey (搜索) has remarkable potential, both on its own, as novel formulations, and in combination with existing antibiotics to tackle AMR."
Addressing a Global Health Crisis
The development comes at a critical time when AMR poses an escalating threat to global health. The World Health Organization considers AMR one of the top 10 global public health challenges, with the potential to cause up to 10 million deaths annually by 2050. In the UK, the government classifies AMR as a "chronic risk," with 35,200 deaths every year attributed to antimicrobial resistance (搜索).
The burden of AMR disproportionately affects certain populations. In New Zealand, Māori and Pacific people are more likely to be hospitalized with infectious illnesses, placing them at greater risk from antibiotic-resistant infections.
International Research Partnership
The collaboration between Aston University and Comvita (搜索) exemplifies the power of international scientific partnerships in addressing global health challenges. Dr Jackie Evans, chief science officer at Comvita, highlighted the significance of the achievement: "This patent marks a major milestone in our mission to advance the science of Mānuka honey (搜索) and unlock its full potential in supporting global health."
Evans emphasized the collaborative model's potential impact: "Our collaboration with Dr Cox reflects the best of science and nature working together and a model for how industry and academia from all corners of the world can work together to solve big problems. As AMR continues to rise worldwide, the need for safe, natural, and effective alternatives has never been greater."
Translating Research into Treatment
The patent filing represents a crucial step toward translating laboratory discoveries into real-world therapeutic applications. Dr Cox noted that the patent filing is "an exciting step toward translating our laboratory discoveries into real-world treatments that could make a meaningful difference for patients globally."
The announcement, made during World Antimicrobial Resistance (搜索) Awareness Week, underscores the shared commitment of New Zealand and the UK to develop novel, effective, and globally relevant solutions to combat AMR.
Her Excellency Iona Thomas, British High Commissioner to New Zealand, praised the collaboration as "a standout example of the strength of UK-New Zealand research partnerships." She added, "AMR is one of the most serious health challenges of our time, and it will take innovative, cross-border thinking to solve it. Seeing world-class researchers and industry leaders come together to advance a nature-based solution is exactly the kind of impact our countries can deliver when we work side by side."